Hong Kong SAR has adopted universal masking, social distancing, testing of all
symptomatic and high-risk groups for isolation of confirmed cases in healthcare facilities …

Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19
patients with hyperinflammatory response; however, there is a lack of systematic review …

Objective: This review was performed to compare the efficacy and safety among hospitalized
patients with COVID-19 who received baricitinib and those who received tocilizumab …

Background Tocilizumab and baricitinib are recommended treatment options for
hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and …

Dexamethasone is a life-saving treatment for severe COVID-19, yet its mechanism of action
is unknown, and many patients deteriorate or die despite timely treatment initiation. Here, we …

Objectives Our aim was to compare outcomes of hospitalized adults with severe COVID-19
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective …

Acute respiratory distress syndrome (ARDS), associated with high mortality rate, affects up to
67% of hospitalized COVID-19 patients. Early evidence indicated that the pathogenesis of …

Background Tocilizumab and baricitinib are immunomodulators that have been repurposed
for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should …

I n December 2019, following the incidence of many cases of viral pneumonia of unknown
origin, a deep sequencing analysis performed on lower respiratory tract samples indicated …

SALAZAR, Martín et al. Utilización precoz de tocilizumab en pacientes internados con
COVID-19 grave y crítica: un estudio multicéntrico en la Provincia de Buenos Aires …